- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03369587
Handwriting Interventions for People With Parkinson's
Background: Problems with handwriting are frustrating and debilitating and affect the majority of people with Parkinson's. Manifest as micrographia it is a distinctive feature of the condition characterised by small handwriting and/or a progressive reduction in size through a sentence[2] coupled with a reduction in writing speed and legibility.
In Parkinson's impaired automaticity is thought to contribute to handwriting deficits and attention has been shown to improve both 'consistent' (small handwriting) and 'progressive' (progressive reduction in letter size through a sentence) aspects of the symptom. Moreover, recent interventional studies indicate handwriting may be improved through practice. This study is investigating a novel handwriting practice stimulus to improve symptoms of micrograpthia
Question: Is a diverging line cued handwriting intervention potentially more effective at improving symptoms of mircograpthia than a parallel line cued handwriting intervention in people with Parkinson's?
Specifically, an assessor blind randomised controlled exploratory trial will:
- Estatimate the effect of the intervention on measures of: Handwriting amplitude (consistent and progressive reduction), hand writing performance and percieved handwriting difficulties.
- Explore the appropriateness of these outcome measures
- Explore the approriateness of eligibilty criteria
- Explore intervention fidelity
- Explore participants views of the intervention
Design: A phase II exploratory randomised controlled trial of a handwriting intervention with an active comparator control group and blinded assessments
Setting: The intervention will be carried out at home
Sample size: This study is not designed to determine efficacy. The aim to recruit a total of 50 people (25 people per group) in order to estimate the effects on outcome measures and achieve the aims of this exploratory trial.
Assessment: Participants will be asked to follow their usual Parkinson's medication regime and if they have ON and OFF periods, assessments will be carried out during ON state.
Duration and follow-up: the assessment is schedule 0Weeks (baseline), 6weeks (end intervention) and 12weeks (follow up). Assessments will be carried out by a researcher blind to trial arm allocation using all outcome measures.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Brescia
-
Darfo Boario Terme, Brescia, Italy, 25041
- European Parkinson's therapy centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Over 18 years old
- Diagnosis of idiopathic Parkinson's disease
- A score of ≤3 on the Hoehn and Yahr scale
- Self-reported problem with handwriting (≥1 UPDRSII, 2.7)
- Able to communicate in Italian
- Following a stable medication regimen (no changes in the last 2 weeks and anticipated changes for the course of the study).
Exclusion Criteria:
- Severe depression or psychosis (history of),
- reduced cognition that would preclude active involvement or capacity to consent (according to stages outlined in metal capacity act (ie trigger, information, existing diagnosis, functional test))
- Orthopaedic, neurological or other condition that significantly impairs hand function,
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Diverging lines
What: Handwriting practice at home delivered through handwriting workbooks.
The workbook consists of diverging lines.
Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines.
Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines.
They will be asked to do this daily, but at least 5 days a week for 6 weeks.
Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
|
Self-directed home handwriting practice daily for 6 weeks
|
|
Active Comparator: Parallel lines
What: Handwriting practice at home delivered through handwriting workbooks.
The workbook consists of parallel lines.
Participants will be instructed to write a daily diary (a reflection of their day) aiming for letters letter size to be consistent with the lines.
Participant will be instructed to take a long as they need to complete the daily diary and focus and concentrate the handwriting and achieving the size dictated by the lines.
They will be asked to do this daily, but at least 5 days a week for 6 weeks.
Tailoring and progression: The nature of the handwriting program is that it accounts for individual ability; participant will be asked to write as much as they can during the practice session, whilst concentrating on their handwriting.
|
Self-directed home handwriting practice daily for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Micrograpthia: Area of 'el' 8 character text sequence writing task
Time Frame: 6 weeks
|
Area (maximum height x maximum width) of handwritten cursive 'elelelel' character sequence measured to the nearest of 0.5mm
|
6 weeks
|
|
Self-reported problem with handwriting: Item 2.7 on the Movement Disorders Society Unified Parkinson's Rating Scale
Time Frame: 6 weeks
|
A scale from 0-4 (0: normal: no problems, 4: severe: most or all words cannot be read) asking 'Over the past week, have people usually had trouble reading your handwriting?'
|
6 weeks
|
|
Writing speed: Time taken to write an Italian proverb
Time Frame: 6 weeks
|
Time taken to the nearest 10th second to hand write the sentence (written across one line): 'Chi lascia la via vecchia per la nuova, sa quello che lascia ma non sa quello che trova'
|
6 weeks
|
|
Writing amplitude: Area of the both 'lascia' contained in an Italian proverb
Time Frame: 6 weeks
|
Area (maximum height x maximum width) of 'lascia' contained in handwritten sentence: 'Chi lascia la via vecchia per la nuova, sa quello che lascia ma non sa quello che trova'.
Measured to the nearest 0.5mm
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Micrograpthia under cognative motor interference: Area of 'el' 8 character text sequence writing task
Time Frame: 6 weeks
|
Area (maximum height x maximum width) of handwritten cursive 'elelelel' character sequence performed concurrently with cognative task (serial 3 subtraction).
Measured to the nearest of 0.5mm
|
6 weeks
|
|
Micrograpthia under cognative motor interference: Area of 'el' 8 character text sequence writing task
Time Frame: 12 weeks
|
Area (maximum height x maximum width) of handwritten cursive 'elelelel' character sequence performed concurrently with cognative task (serial 3 subtraction).
Measured to the nearest of 0.5mm
|
12 weeks
|
|
Legibility of Free writing
Time Frame: 6 weeks
|
Ratio between total number of words written and total number of legible words written during a 5 minutes of free writing task: A reflection on the day
|
6 weeks
|
|
Legibility of Free writing
Time Frame: 12 weeks
|
Ratio between total number of words written and total number of legible words written during a 5 minutes of free writing task: A reflection on the day
|
12 weeks
|
|
EQ-5D-5L
Time Frame: 6 weeks
|
Standardized Instrument to measure health outcome
|
6 weeks
|
|
EQ-5D-5L
Time Frame: 12 weeks
|
Standardized Instrument to measure health outcome
|
12 weeks
|
|
Micrograpthia: Area of 'el' 8 character text sequence writing task
Time Frame: 12 weeks
|
Area (maximum height x maximum width) of handwritten cursive 'elelelel' character
|
12 weeks
|
|
Self-reported problem with handwriting: Item 2.7 on the Movement Disorders Society
Time Frame: 12 weeks
|
0-4 scale (0: normal: no problems, 4: severe: most or all words cannot be read) asking 'Over the past week, have people usually had trouble reading your handwriting?'
|
12 weeks
|
|
Writing speed: Time taken to write an Italian proverb
Time Frame: 12 weeks
|
Time taken to the nearest 10th second to hand write the sentence (written across one line): 'Chi lascia la via vecchia per la nuova, sa quello che lascia ma non sa quello che trova'
|
12 weeks
|
|
Writing amplitude: Area of the both 'lascia' contained in an Italian proverb
Time Frame: 12 weeks
|
Area (maximum height x maximum width) of 'lascia' contained in handwritten sentence: 'Chi lascia la via vecchia per la nuova, sa quello che lascia ma non sa quello che trova'.
Measured to the nearest 0.5mm
|
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 171073
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
ProgenaBiomeWithdrawnParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
Clinical Trials on Handwriting Practice
-
Chang Gung Memorial HospitalCompleted
-
University of Alabama at BirminghamCompletedTourette Syndrome | Tic DisordersUnited States
-
University of Applied Sciences for Health Professions...University of Wisconsin, MilwaukeeCompleted
-
National Taiwan University HospitalCompletedAutism Spectrum DisorderTaiwan
-
Shirley Ryan AbilityLabJames Madison UniversityCompleted
-
Sara Llamas VelascoCarlos III Health InstituteCompletedPARKINSON DISEASE (Disorder)Spain
-
Misr University for Science and TechnologyEnrolling by invitation
-
Shenandoah UniversityCompletedHealthy ChildrenUnited States
-
Milton S. Hershey Medical CenterBioSensicsRecruitingAmyotrophic Lateral Sclerosis | Primary Lateral Sclerosis | Progressive Muscular AtrophyUnited States